Showing results (181-190 of 319) with videos related to
Sort By:
Pageof 32
Epigenetics|March 8, 2012
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemiaJumpei Yamazaki, Rodolphe Taby, Aparna Vasanthakumar, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 15, 2011
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationKoen van Besien, Wendy Stock, Elizabeth Rich, et al.Cancer Causes & Control : CCC|June 20, 2006
Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States)Jacob H Cohen, Victor J Schoenbach, Jay S Kaufman, et al.Leukemia & Lymphoma|August 3, 2018
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantationChristopher R D'Angelo, Brianna Novitsky, Sang Mee Lee, et al.Ethnicity & Health|July 4, 2017
Black Pastors' Views on preaching about sex: barriers, facilitators, and opportunities for HIV prevention messagingAdaora A Adimora, Moses V Goldmon, Tamera Coyne-Beasley, et al.Stem Cell Reports|May 21, 2021
Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell modelSara Borst, Catriana C Nations, Joshua G Klein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma, Maria R Baer, James L Slack, et al.Journal of Oncology Practice|November 14, 2018
Treatment of Acute Promyelocytic Leukemia in AdultsAfaf E G Osman, Jennifer Anderson, Jane E Churpek, et al.Leukemia & Lymphoma|March 11, 2017
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemiaNiloufer Khan, Andrew Hantel, Randall W Knoebel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2011
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stageAnna Woloszynska-Read, Wa Zhang, Jihnhee Yu, et al.Pageof 32